Quick Facts

• Support for Chemotherapy: May be used to help decrease the potential for infection, which can manifest as febrile neutropenia, in individuals receiving certain anti-cancer therapies.
• Acute Myeloid Leukemia (AML): May contribute to reducing the time needed for neutrophil recovery following specific induction or consolidation chemotherapy treatments.
• Severe Chronic Neutropenia: Used for the long-term management of conditions involving low neutrophil counts, which may help lessen the frequency and duration of related complications, such as infections and fever.
• Stem Cell Support: Utilized to mobilize hematopoietic progenitor cells into the bloodstream prior to collection procedures.

---

Leucogen is a therapeutic agent that may be recommended in clinical situations requiring support for blood cell production. Its use is generally focused on managing conditions associated with a low count of a specific type of white blood cell, the neutrophil (neutropenia).

For individuals with non-myeloid malignancies undergoing certain myelosuppressive chemotherapy, this treatment may be used to help decrease the incidence of infection. The medication is also utilized in patients receiving myeloablative chemotherapy followed by a bone marrow transplant to potentially reduce the duration of neutropenia and its related clinical outcomes, such as febrile neutropenia.

Furthermore, this therapeutic approach may be appropriate for the chronic management of symptoms in patients diagnosed with severe chronic neutropenia, including congenital, cyclic, or idiopathic types. It may help lessen the incidence and duration of sequelae of severe neutropenia, which includes fever and infections. The use and indications of this class of medication are subject to regulatory oversight.

Who can and cannot use Leucogen (Hematopoietic)?

Official regulatory documents define strict population eligibility for Leucogen (Filgrastim), ensuring its use aligns with approved patient profiles and conditions.

---

Eligibility Restrictions and Contraindications

Classification	Population/Condition
Contraindicated	Patients with a known history of serious allergic reactions or hypersensitivity to Filgrastim, any product components, or E. coli-derived proteins (as stated in labeling).
Use Not Recommended	Patients with Chronic Myeloid Leukemia (CML) or Myelodysplastic Syndromes (MDS) due to the potential for stimulating malignant cell growth.
Special Restriction	Patients with Sickle Cell Disease or Sickle Cell Trait; use is restricted due to the specific, labeled risk of fatal sickle cell crises.

---

Age and Physiological Status

Population Group	Regulatory Status
Pediatric Patients	Use is established and approved for most indications in children 1 month and older; safety in neonates has not been established.
Older Adults	Use is permitted, but specific dosage recommendations are not provided due to limited dedicated studies.
Pregnancy	Restricted use; the medicine should only be used if the potential benefit justifies the potential risk to the fetus.
Organ Impairment	Patients with severe renal or hepatic impairment are generally eligible, as official documents indicate no dose adjustment is required.

Interactions with other medicines and products

Leucogen, a hematopoietic agent, has a focused interaction profile primarily governed by its biological mechanism of action, which involves stimulating the production and proliferation of white blood cells. This effect requires careful timing when used alongside specific classes of medicines.

Medicinal Product Categories with Documented Interactions

• Myelosuppressive Anti-cancer Drugs: This category includes cytotoxic chemotherapy agents that suppress bone marrow activity. The core concern is a pharmacodynamic interaction, where the concurrent use of a hematopoietic stimulant could enhance the sensitivity of rapidly dividing myeloid cells to the cytotoxic effects of chemotherapy.

• Other Hematopoietic Growth Factors: Use with other growth factors intended for chemotherapy-induced myelosuppression (e.g., G-CSF, GM-CSF) is generally avoided unless specifically directed, due to potential additive or compounding effects.

Timing-Based Interaction Rules and Restrictions

Regulatory information emphasizes the critical need for a time separation between Leucogen and cytotoxic agents. As a procedural constraint for this drug class, Leucogen is not to be administered within the 24-hour period immediately before or after the administration of myelosuppressive chemotherapy. This rule is designed to prevent the drug-induced stimulation of cell production from increasing the destruction of bone marrow cells by the chemotherapy.

No formal pharmacokinetic interaction statements (involving metabolism or transport) are broadly noted in general regulatory summaries for Leucogen. The clinical safety and efficacy of the combination of Leucogen with other specific medicines should be reviewed on a case-by-case basis based on complete official labeling.

The mechanism of action for Leucogen (Filgrastim) is highly specific, based on its role as a full agonist that directly targets and activates the Granulocyte Colony-Stimulating Factor Receptor ( G-CSF-R). This action drives a profound systemic change by initiating three distinct, interconnected biological processes within the bone marrow.

Activating Granulopoiesis via JAK/STAT Signaling

The initial binding of Filgrastim to the G-CSF-R triggers the activation of crucial intracellular signaling pathways, principally the JAK/STAT cascade. This molecular command drives the rapid proliferation and differentiation of myeloid precursor cells, accelerating the entire production line of neutrophils (a process known as granulopoiesis). This mechanism leads to an increased output and circulation time of mature neutrophils.

Enhancing Neutrophil Mobilization and Release

In addition to stimulating production, the mechanism involves modulating the cellular retention signals mediated by the CXCL12-CXCR4 axis within the bone marrow. By temporarily overriding this molecular anchor, Filgrastim facilitates the enhanced mobilization of both stored and newly formed neutrophils, promoting their rapid entry into the peripheral circulation. This dual action of increased production and accelerated release results in a significant rise in the Absolute Neutrophil Count (ANC) in the peripheral circulation.

How to Use Leucogen (Hematopoietic)

Leucogen, which contains the active substance filgrastim, is administered through either a subcutaneous injection (under the skin) or an intravenous (IV) infusion (into a vein). The official administration schedule is strictly defined by the clinical context, dictating the precise dose and timing.

Official Administration Guidelines

Administration Scope	Regulatory Instruction (Daily)
Route of Administration	Subcutaneous injection or Intravenous Infusion
Standard Dosing (e.g., Post-Chemotherapy)	Recommended starting dose is 5 mu g/kg/day
Timing Relative to Chemotherapy	Administer at least 24 hours after cytotoxic chemotherapy.
Timing Constraint	Do not administer within the 24-hour period prior to chemotherapy.

For patients undergoing Bone Marrow Transplantation, the recommended daily dose is higher at 10 mu g/kg/day as an IV infusion, which should not exceed 24 hours. The first dose must be given at least 24 hours after both the cytotoxic chemotherapy and the bone marrow infusion.

For Autologous Peripheral Blood Progenitor Cell (PBPC) Collection, the dose is also 10 mu g/kg/day given by subcutaneous injection, starting at least four days before the first leukapheresis procedure and continuing until the last procedure is completed.

This mandatory daily protocol, with its specific weight-based dosage and timing constraints relative to other treatments, defines the standardized use of the medicine.

Leucogen, a derivative of L-cysteine, is studied for its role in stimulating bone marrow hematopoietic function, primarily to manage leukopenia (low white blood cell count) and thrombocytopenia (low platelet count).

Studies in Chemotherapy-Induced Leukopenia

Clinical research on Leucogen has largely focused on patients undergoing chemotherapy, where a drop in white blood cell (WBC) count is a common side effect. Studies evaluated its effect, often in combination with Granulocyte Colony-Stimulating Factor (G-CSF), on reducing the risk of febrile neutropenia (FN).

A Phase II study that investigated Leucogen in a subgroup of chemotherapy patients reported that the intervention was associated with an incidence of FN of 0% in the study cohort. However, the authors noted the need for randomized Phase III studies to confirm this finding and fully capture all known risk factors for developing FN.

Evidence in Other Hematological Conditions

Research has explored the use of Leucogen in other conditions marked by hematopoietic compromise, such as alcoholic liver cirrhosis (ALC) with associated leukopenia and/or thrombocytopenia. A retrospective study in ALC patients, which compared a Leucogen group to a non-Leucogen group, reported a significantly higher proportion of patients in the Leucogen group experienced an increase in both platelet (PLT) and WBC counts after three months of treatment. The study also characterized the safety profile as favorable, noting that the drug was particularly associated with improvements in younger patients and those with lower baseline liver enzyme levels. This study, being retrospective, highlights the need for prospective, controlled trials.

Common questions about Leucogen (Hematopoietic) (FAQ)

Q: How quickly does Leucogen start working after I begin treatment?

According to official product information, the initial onset of the drug’s action, which is the stimulation of white blood cell production, is generally reported as occurring within 1 to 2 days after the first administration. This timeframe is consistent with the drug’s intended role as an agent to quickly stimulate white blood cell production.

Q: Is Leucogen the same drug as Neupogen or Neulasta?

Leucogen is a brand name for the active ingredient, Filgrastim, which is the non-proprietary name. The drug Neupogen is also a brand name for Filgrastim. The drug Neulasta contains Pegfilgrastim, which is a modified form of Filgrastim with different administration and duration characteristics.

Q: Does Leucogen interact with common over-the-counter pain relievers like ibuprofen?

Regulatory documents indicate that formal interaction studies focusing on Filgrastim and non-cytotoxic agents (drugs that are not chemotherapy) have generally not been performed or widely reported. Regulatory guidance emphasizes the importance of disclosing all medications, including non-prescription drugs, to a healthcare provider.

Q: Can Leucogen be taken with blood pressure medication?

Official drug interaction summaries focus heavily on cytotoxic agents (chemotherapy) and other growth factors. Formal interaction studies with non-cytotoxic medications, such as blood pressure medicines, have generally not been performed or reported in regulatory documents.

Q: Does Leucogen work for all types of low blood cell counts?

Filgrastim is classified as a Granulocyte Colony-Stimulating Factor (G-CSF), meaning it primarily targets the production of neutrophils (a specific type of white blood cell). The primary approved use of Filgrastim is for low neutrophil counts (neutropenia).

Q: What happens if Leucogen is accidentally frozen?

Official storage instructions state that the medicine must not be frozen. If the product is accidentally frozen, official storage requirements indicate it should not be used, as freezing may compromise the product’s stability and effectiveness.

Q: Does Leucogen have a generic or non-branded version?

Yes, the active ingredient in Leucogen is Filgrastim. Filgrastim is the non-proprietary name for the drug and is the name used for generic or biosimilar versions of the medicine.

Q: Is it normal for my spleen to enlarge slightly while on Leucogen?

Splenomegaly (an enlarged spleen) is documented as a common adverse reaction reported with the use of Filgrastim. The official labeling also highlights severe adverse events, including splenic rupture, as a safety consideration.

Q: How do doctors check if Leucogen is actually working for a patient?

The effectiveness of the medicine is monitored by measuring the level of white blood cells in the patient’s blood. Specifically, clinical efficacy is assessed by tracking the Absolute Neutrophil Count (ANC), which helps guide dose adjustments or discontinuation of treatment.

Q: Is the research evidence for Leucogen considered strong?

The use of Filgrastim is supported by clinical studies, including randomized trials. While the use of Filgrastim is supported by clinical studies, some official regulatory documents indicate that long-term consequences and safety profiles require further review.

Q: Where can I find the official regulatory information about Leucogen?

Official regulatory information is detailed in government-mandated documents. These include the full drug description, such as the FDA Label, the Summary of Product Characteristics (SmPC) used in Europe, and information provided by national drug registries.

Q: What is the most frequently reported side effect of Leucogen in clinical trials?

In clinical trials and official safety profiles, bone pain is cited as the most common adverse event. It is a very common side effect reported consistently across patient populations.

Q: Why is Leucogen referred to as 'Hematopoietic'?

The drug's name includes 'Hematopoietic' because this term refers to the process of forming blood cellular components. Filgrastim’s primary function is stimulating the bone marrow to produce white blood cells, placing it within the class of hematopoietic agents.

Q: How long does the effect of Leucogen last?

Filgrastim has an elimination half-life of approximately 3.5 hours. Given the elimination half-life is approximately 3.5 hours, when the medicine is stopped, neutrophil counts typically decrease rapidly, returning to pre-treatment levels within 1 to 7 days.

Q: Can Leucogen affect my red blood cells, or only my white blood cells?

Filgrastim primarily acts as a growth factor for white blood cells (neutrophils) and is not approved for stimulating red blood cell production. Its effects are primarily limited to white blood cells. Filgrastim is not approved for stimulating red blood cell production.

Q: What is the general difference between Leucogen and a stem cell boost?

Leucogen is a drug (a growth factor) that works on the body’s own system. It can be used to help move hematopoietic progenitor cells (which are early stem cells) from the bone marrow into the bloodstream so they can be collected, but the drug itself is not a stem cell.

Q: Can men use Leucogen if they are trying to conceive?

Official documentation reports that non-clinical studies performed in male and female rats found that Filgrastim had no observed effect on fertility or reproductive performance. However, data concerning the effects on human fertility are generally not available.

Q: Are there certain supplements or vitamins that should not be taken with Leucogen?

Regulatory guidance indicates the importance of disclosing all products to a healthcare provider. This includes not only prescription and non-prescription medicines but also any vitamins, nutritional supplements, and herbal products.

Q: Is there a maximum time someone can stay on Leucogen treatment?

No universal maximum time for treatment is specified in regulatory documents. Instead, the duration of use is determined by the specific clinical condition, such as up to 2 weeks for post-chemotherapy use, or until the neutrophil count has recovered.

Q: Does Leucogen have any known interaction with alcohol?

Formal, specific interactions between Filgrastim and alcohol are not typically listed in the core regulatory documents. However, patient-facing information often suggests discussing alcohol consumption with a healthcare provider while on treatment.

Q: What is the purpose of the 'Leucogen' part of the name?

The brand name utilizes the term 'Leucogen' to reflect the drug’s function. The prefix 'Leuco-' refers to leukocytes (white blood cells), and the drug's intended purpose is to 'gen' (generate or produce) these cells.

Q: Does Leucogen affect my ability to drive or operate machinery?

Official regulatory information indicates that Filgrastim may have a minor influence on a person's ability to drive or use machinery. Official warnings note that if side effects like dizziness occur, a person's ability to drive or use machinery may be impaired.

Q: What distinguishes Leucogen from growth factors used for red blood cells?

Leucogen (Filgrastim) is a Granulocyte Colony-Stimulating Factor (G-CSF) that specifically regulates neutrophil (white blood cell) production. This places it in a different pharmacological class than growth factors used for red blood cells (known as erythropoietins), which target erythroid cells.

How to Store and Dispose of Leucogen (Hematopoietic)?

Leucogen, a solution containing the active ingredient Filgrastim, must be stored under specific environmental conditions to maintain its efficacy, as defined by regulatory labeling.

Official Storage Conditions

Requirement	Condition
Temperature	Store in a refrigerator between 2 C and 8 C (Do not freeze).
Protection	Keep in the original outer carton to protect the product from light.
Child Safety	Keep out of the sight and reach of children.

The medicine may be stored at room temperature (not above 25 C) for a single period of up to 7 days, but it cannot be returned to the refrigerator after this temporary storage.

Disposal

Do not throw away unused or expired product via household waste or wastewater. Disposal must follow local guidelines for pharmaceutical waste, often requiring return to a pharmacy or authorized collection point.